Merck & Company, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert M. Davis
- Full Time Employees
- 75,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 126 East Lincoln Avenue Rahway NJ United States 07065
- IPO Date
- Jan 1, 1941
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Company News
Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp
November Dogs Of The Dow: No Buys, Yet 5 Are Worth Watching
AIA Group Ltd Sells 55,326 Shares of Merck & Co., Inc. $MRK
6,400 Merck & Co., Inc. $MRK Shares Purchased by Aware Super Pty Ltd as trustee of Aware Super
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial
Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Merck & Co., Inc. $MRK Shares Bought by International Assets Investment Management LLC
Moderna, Merck eye FDA approval for promising cancer vaccine
Founders Financial Securities LLC Sells 3,449 Shares of Merck & Co., Inc. $MRK
Why Merck Stock Flew Higher on Friday
Merck One of Top Large-Cap Biopharma Picks-Analyst
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook